South Korea to Mandate ‘Use-By Period After Opening’ on Blood Glucose Test Strip Packaging
On
July 28, 2025, South Korea’s Ministry of Food and Drug Safety (MFDS) announced
the reissue of a partial amendment to the Enforcement Rule of the In Vitro
Diagnostic Medical Devices Act. The amendment aims to improve the quality and
infrastructure of newly developed in vitro diagnostic medical devices (IVDs)
and address gaps in the current system.
Key
Changes
- Approval fees for new IVDs will be revised, with provisions for fee
reductions.
- Applicants for manufacturing licenses or modifications will be
exempt from resubmitting verified quality manager qualification documents.
- Packaging of personal blood glucose test strips must indicate the
period of use after opening.
- The Class I IVD management system will move to a notification-based
process with a five-day processing period.
Institutions,
organizations, and individuals may submit opinions on the amendment online or
by sending a written statement to MFDS by September 8, 2025.
For inquiries about South Korea’s regulations on in vitro diagnostic medical devices, please contact GCA KOREA. As a trusted partner for KC certification and IVD regulatory compliance, we are committed to supporting your successful market entry. For the latest updates on Korea’s Medical Devices Act, including recent proposed revisions, please visit our official website.
Comments
Post a Comment